Topics

Advances in AI-Driven Tumor Epitope Prediction

Cancer Immunotherapy DNA Metabolism And Repair Proteostasis Intercellular Communication & Diseases

Artificial intelligence is increasingly used to rank tumor epitopes for personalized vaccines and T-cell therapies. The task is a multistep prediction problem: identify a true somatic alteration, confirm expression, determine protein processing, predict peptide transport and HLA binding, estimate peptide–MHC stability, and assess whether a T-cell repertoire can recognize the complex. Early tools focused heavily on binding affinity; newer machine-learning models integrate sequence, HLA context, immunopeptidomics, and immunogenicity. DeepHLApan exemplifies attempts to consider both binding and immune recognition. AI can reduce a vast candidate space, but a high model score is not evidence that the epitope is naturally presented or therapeutically useful The clinical cost of false prioritization is high because every weak candidate consumes manufacturing capacity and reduces space for epitopes that could generate tumor control[1][2][3].

Models learn patterns from binding assays, eluted HLA ligands, T-cell assays, structures, and clinical datasets. Neural networks can capture nonlinear interactions between peptide and HLA sequence and generalize across alleles when training data are adequate. However, common HLA alleles and strong binders dominate available data, creating bias against rare alleles, class II epitopes, post-translational modifications, and low-abundance but relevant peptides. Negative examples are often uncertain because failure to observe a response may reflect assay sensitivity rather than true nonimmunogenicity. Data leakage and inconsistent train–test splitting can make performance appear better than prospective use Prospective performance often falls when a model encounters new laboratories, sequencing pipelines, HLA alleles, or tumor types not represented in its training distribution[1][2][3].

Applications include selecting vaccine peptides, prioritizing TCR targets, designing multivalent constructs, and identifying shared neoantigens. A clinical pipeline should combine AI with tumor-normal sequencing, RNA expression, clonality, HLA typing, and mass-spectrometry or cellular validation when feasible. Patient-specific ranking must also consider manufacturing time and tumor evolution. Models can optimize population coverage or reduce predicted cross-reactivity, but normal-proteome screening and primary-cell testing remain necessary. Generative approaches may improve peptide design, yet altered ligands can recruit T cells that fail to recognize the natural tumor epitope AI can also integrate peptide toxicity and similarity to essential normal proteins, supporting safety triage before expensive receptor isolation or vaccine manufacture[1][2].

Future progress requires prospective benchmarks with blinded, experimentally verified candidates and complete reporting of failures. Evaluation should separate HLA binding, presentation, T-cell recognition, and tumor killing rather than collapse them into one accuracy metric. Diverse HLA populations and standardized immunopeptidomic datasets are essential for equity and generalizability. Interpretable uncertainty estimates can help decide which predictions need laboratory confirmation. Clinical trials should track predicted clonotypes into tumor and link them to response. AI will be most valuable as an auditable decision-support layer that integrates evidence and prioritizes experiments, not as a replacement for biological validation of antigen processing and immune recognition Public datasets should include negative and null experimental results so that algorithms learn biological boundaries instead of only patterns among successful discoveries. Model cards should document training cohorts, allele coverage, assay definitions, calibration, and known failure modes so clinicians can interpret a ranking safely in its intended clinical domain[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-13259 MG-132
MG-132 (Z-Leu-Leu-Leu-al) is a potent proteasome and calpain inhibitor with IC50s of 100 nM and 1.2 μM, respectively. MG-132 effectively blocks the proteolytic activity of the 26S proteasome complex. MG-132, a peptide aldehyde, also is an autophagy activator. MG-132 also induces apoptosis.
Proteasome   Autophagy   Apoptosis  
Cancer  
2185
HY-10227 Bortezomib
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
Proteasome   NF-κB   Apoptosis   Autophagy   TREM receptor   Ligands for Target Protein for PROTAC  
Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Obesity  
271
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,212 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

99
HY-L028 CNS-Penetrant Compound Library
The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneficial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy. MCE offers a unique collection of 1,158 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

Compound Characteristic Classified Libraries

91
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 820 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L017 Stem Cell Signaling Compound Library
Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy. MCE owns a unique collection of 2,906 compounds that can be used for stem cell regulatory and signaling pathway research.

Signaling Pathway Targeting Libraries

86
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,042 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L083 Anti-Cancer Metabolism Compound Library
Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth. MCE provides a unique collection of 3,773 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

Signaling Pathway Targeting Libraries

84
HY-L188 Anti-Brain Cancer Compound Library
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets. MCE designs a unique collection of 2,113 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
84
HY-L0119V Asinex PPI Pre-Plated Library
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures. The PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics. The designs cover β-turn / loop mimetics and α-helix mimetics. Since helices present at the interface in 62% of all protein-protein interactions. This library focused on designs including mimics with the substitution geometry of an a-helices, as well as designs that mimic the location of “hot-spot” side chains in helix-mediated PPIs.
83
HY-L074 Anti-Breast Cancer Compound Library
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 3,382 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Disease Focused Libraries

83
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,302 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L097 Animal Disease Model Inducer Library
Animal disease models are used in a variety of settings in basic research, such as studies on mechanisms of disease progression and evaluation new drugs. Animal models can be broadly classified into five categories: 1) experimental, 2) spontaneous, 3) negative, 4) orphan, 5) genetically engineered. Experimental models, which are induced artificially in the laboratory, are most common. Some small molecular compounds are usually used as inducers for animal models, such as Ceruletide for inflammatory model, Azoxymethane for tumor model. These inducers are useful tool in building animal models. MCE offers a unique collection of 52 animal model inducers, involving inflammatory model, tumor model, nervous disease model, etc. MCE Animal Disease Model library is a powerful tool for the establishment of animal disease models.

Compound Characteristic Classified Libraries

83
HY-L103 Anti-Colorectal Cancer Compound Library
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,632 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L135 Cancer Stem Cells Compound Library
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on. Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment. MCE supplies a unique collection of 3,524 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Compound Characteristic Classified Libraries

83
HY-L161 Cytokine Inhibitors Library
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases. MCE designs a unique collection of 1,406 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.

Signaling Pathway Targeting Libraries

83
HY-L173 Anti-Ovarian Cancer Compound Library
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer. MCE designs a unique collection of 2,955 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Disease Focused Libraries

83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 268 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L918 Molecular Glue-like Compound Library
Targeted Protein Degradation (TPD) is a novel and promising approach to drug development. It shows great potential for targeting proteins traditionally considered "undruggable" due to the lack of enzymatic function and absence of binding sites by tagging them for degradation or recruiting natural degradation mechanisms. Molecular glues are a type of small-molecule degraders that primarily induce novel interactions between E3 ubiquitin ligases and target proteins, forming ternary complexes that lead to protein ubiquitination and subsequent proteasomal degradation. Compared with PROTACs, molecular glues generally have lower molecular weights, higher cell permeability, and better drug-like properties. Additionally, the design of molecular glues is relatively simple, without the requirements for complex linkers and ligand optimization. As a result, molecular glues have gradually emerged as a promising therapeutic approach for various diseases. Multiple types of molecular glues have been reported previously. Analysis of co-crystal complex structures reveals that CRBN-related molecular glues are more versatile. Therefore, MCE researchers select active molecules related to these targets as probes for artificial intelligence (AI) screening.Subsequently, molecular docking technology was used to verify whether the screened molecules retained the key pharmacophore features. Ultimately, we obtained 317 molecular glue analogs, and these compounds serve as powerful tools for the research of molecular glues.

Focused and target libraries

83
HY-L919 MCE CNS BBB Lead-like Library
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

Focused and target libraries

83
HY-L920 CNS MPO Lead-like Library
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. The CNS MPO (Multi-Parameter Optimization) score is a widely recognized algorithm in medicinal chemistry. Developed by Pfizer, this method is based on an analysis of approved CNS drugs and their interior CNS drug candidates, establishing the CNS MPO rules. It incorporates six key physicochemical properties (ClogP, ClogD, MW, TPSA, HBD, and pKa) to prospectively optimize CNS drug attributes—such as high blood-brain barrier (BBB) permeability, low P-gp efflux liability, low metabolic clearance, and high safety—thereby improving the clinical success rate of CNS drug candidates. The CNS MPO compound library is a collection of compounds with CNS MPO scores greater than 5, specifically designed for CNS drug discovery.

Focused and target libraries

83
HY-L922 Good ADMET Diversity Library
A diverse compound library with favorable ADMET properties (Absorption, Distribution, Metabolism, Excretion, and Toxicity) is crucial in drug discovery. Early evaluation of ADMET properties allows for the exclusion of molecules with unfavorable profiles at the initial stages, thereby reducing the risk of late-stage development failures, lowering R&D costs, and accelerating optimization of lead compounds. Based on predictions from ADMET-related AI algorithms, the compounds in this library are predicted to exhibit favorable oral bioavailability (F > 30%), reasonable plasma protein binding (PPB < 98%), minimized CYP3A4 inhibition potential (inhibition probability < 50%, CYP3A4 is the most critical drug-metabolizing enzyme in the cytochrome P450 family) , low toxicity profiles, with 140 potentially toxic substructures pre-identified and excluded via substructure searching to eliminate compounds containing hazardous fragments. The diversity library enables broad applicability in high-throughput screening (HTS) and high-content screening (HCS).

Distinctive Diversity Libraries

83
HY-L923 Ion Channel Lead-like Compound Library
Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields. MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.

Focused and target libraries

83
HY-10455 Carfilzomib
Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.
Proteasome   Autophagy   Apoptosis  
74
HY-13067 Celastrol
Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH.
Proteasome   Autophagy   Mitophagy   Apoptosis   Endogenous Metabolite   Antibiotic   Bacterial   Nuclear Hormone Receptor 4A/NR4A  
Cancer   Infection   Inflammation or Immune System Disease  
66
HY-123606 GSK484
GSK484 is a PAD4 inhibitor that effectively inhibits protein citrullination and the formation of neutrophil extracellular traps (NETs) by blocking the catalytic activity of PAD4. GSK484 suppresses the production of histone H3, MHC-I expression, CD8+ T cell activation, proliferation and inflammatory cytokine release. GSK484 reduces inflammation and bone destruction in collagen-induced rheumatoid arthritis, alleviates pain and mast cell activation in sickle cell disease, and improves myocardial ischemia-reperfusion injury and experimental colitis. In addition, GSK484 restores intestinal microbial homeostasis by reversing ferroptosis-induced dysbiosis. GSK484 can be used to study the disease mechanisms of rheumatoid arthritis, sickle cell disease, thrombosis, myocardial injury, colitis and other conditions.
Protein Arginine Deiminase   MHC  
Digestive System Disease   Colitis   Sickle Cell Disease   Cardiomyopathy   Rheumatoid Arthritis  
54
HY-Y1883 Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant
Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a non-denaturing detergent that solubilizes lipid membranes. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is commonly used in laboratories and is applied to vaccines at different stages of the manufacturing process. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is listed as an excipient in certain vaccines including split virus influenza vaccines. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a nonionic surfactant. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant induces Apoptosis in prostate and colon cancer cell lines and reduces the infectivity of classic enveloped viruses such as WNV.
Environmental Pollutants   Apoptosis   Biochemical Assay Reagents  
Colorectal Cancer   Prostate Cancer   Viral Infection  
28
HY-100223 Calpeptin
Calpeptin is a potent, cell penetrating calpain inhibitor, with an ID50 of 40 nM for Calpain I in human platelets. Calpeptin is also an inhibitor of cathepsin K.
Cathepsin   Proteasome   Apoptosis  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation  
28
HY-13821 Epoxomicin
Epoxomicin (BU-4061T) is an epoxyketone-containing natural product and a potent, selective and irreversible proteasome inhibitor. Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome and potently inhibits primarily the chymotrypsin-like activity. Epoxomicin can cross the blood-brain barrier. Epoxomicin has strongly antitumor and anti-inflammatory activity.

Source: actinomycete strain NumberQ996-17

Proteasome   Apoptosis  
Cancer   Inflammation or Immune System Disease  
27
HY-K6002 Basement Membrane Matrix

MCE Basement Membrane Matrix is primarily composed of natural basement membrane matrix extracted from mouse tumors.This product is mainly used for studies of tumor invasion, angiogenesis and organoids culture while avoiding color interference in subsequent experiments.

Cell Biology 3D Cell Culture Basement Membrane Matrix

24
HY-10453 Ixazomib
Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM).
Proteasome   Autophagy  
Leukemia/Lymphoma/Myeloma   Viral Infection   SARS-CoV-2 Infection   Lung Fibrosis  
23
HY-P1489A OVA Peptide(257-264) TFA
OVA Peptide(257-264) TFA is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
22
HY-P1489 OVA Peptide(257-264)
OVA Peptide(257-264) is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide can be from ovalbumin presented by the class I MHC molecule, H-2Kb.
MHC  
Inflammation or Immune System Disease  
22
HY-K6001 Basement Membrane Matrix (Phenol Red)

MCE Basement Membrane Matrix (Phenol Red) is primarily composed of a natural basement membrane matrix derived from mouse tumors. This product is mainly for studies of tumor invasion, angiogenesis, and organoid culture.

Cell Biology 3D Cell Culture Basement Membrane Matrix

21
HY-N2117 Isoginkgetin
Isoginkgetin is a pre-mRNA splicing inhibitor inhibitor. Isoginkgetin also inhibits activities of both Akt, NF-κB and MMP-9. Isoginkgetin inhibits the activity of the 20S proteasome, induces apoptosis and activates autophagy.
MMP   Akt   NF-κB   Proteasome   Apoptosis   Autophagy  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis  
20
HY-13259C (R)-MG-132
(R)-MG-132 ((S,R,S)-(-)-MG-132) is the enantiomer of MG-132. (R)-MG-132 is a proteasome inhibitor with weaker cell cytotoxicity than MG-132.
Proteasome  
Cancer  
18
HY-P1002 Suc-Leu-Leu-Val-Tyr-AMC
Suc-Leu-Leu-Val-Tyr-AMC is a membrane-permeable calpain-specific fluorogenic substrate (Ex/Em = 390/480 nm).
Fluorescent Dye   Proteasome  
16
HY-101092 QS-21-Api
QS-21-Api, an immunostimulatory saponin, could be used as a potent vaccine adjuvant. QS-21-Api stimulates Th2 humoral and Th1 cell-mediated immune responses through action on antigen presenting cells (APCs) and T cells. QS-21-Api can activate the NLRP3 inflammasome with subsequent release of caspase-1 dependent cytokines, IL-1β and IL-18.
NOD-like Receptor (NLR)  
Inflammation or Immune System Disease  
8
HY-123941 FKBP12 PROTAC dTAG-7
FKBP12 PROTAC dTAG-7 (dTAG-7) is a FKBP12F36V PROTAC degrader. FKBP12 PROTAC dTAG-7 binds FKBP12F36V and CRBN to form a complex, mediating degradation via the ubiquitin-proteasome system. FKBP12 PROTAC dTAG-7 mediates the degradation of FKBP12F36V-tagged nuclear and cytoplasmic proteins, including BRD4, HDAC1, EZH2, MYC, PLK1, KRASG12V, and antigen fusion proteins. FKBP12 PROTAC dTAG-7 enhances MHC class I antigen presentation. FKBP12 PROTAC dTAG-7 is applicable to leukemia-related research.
PROTACs   FKBP   Epigenetic Reader Domain   HDAC   Histone Methyltransferase   c-Myc   Polo-like Kinase (PLK)   Ras   MHC  
Leukemia/Lymphoma/Myeloma  
4
HY-P7696 CA125 Protein, Human (HEK293, His)
CA125 is a giant mucin-like glycoprotein expressed by epithelial ovarian neoplasms and cells, which is an antigenic tumor marker. CA125 provides a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. CA125 binds to mesothelin (MSLN) mediates heterotypic cell adhesion, contributing to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium. CA125 is widely used for monitoring with ovarian epithelial cancer. CA125 Protein, Human (HEK293, His) is a recombinant human cancer antigen 125 (CA125) with a His label and is expressed in HEK293 cells.

Species: Human; Source: HEK293

CAR-T Related Proteins CA-125

4
HY-N4087 Platycodin D2
Platycodin D2 is an orally active triterpenoid saponin found in Platycodon grandiflorum. Platycodin D2 induces mitophagy in cancer cells through NIX, thereby activating the P21/CyclinA2 pathway and promoting cell senescence. Platycodin D2 induces mitochondrial dysfunction, enhances autophagy, inhibits hepatocellular carcinoma cell proliferation, and exhibits anti-tumor activity against multiple cancer cell types. Platycodin D2 promotes mRNA expression of T-bet, GATA-3, Th1 cytokines IL-2 and IFN-γ, and Th2 cytokines IL-4 and IL-10, enhances splenocyte proliferation, and acts as a vaccine adjuvant with low rabbit red blood cell hemolytic activity. Platycodin D2 induces mitochondrial ROS production, incomplete autophagy, and ferroptosis to inhibit breast cancer cell proliferation. Platycodin D2 can be used for the research of cancer, inflammation and immunology.
Mitophagy   Autophagy   Ferroptosis   Interleukin Related   IFNAR   Reactive Oxygen Species (ROS)  
Cancer   Inflammation or Immune System Disease  
3
HY-139579 Pafolacianine
Pafolacianine (OTL 38) is a fluorescent imaging agent made of near-infrared dye used in detecting tumor lesions during surgical procedures. Pafolacianine excites at 774 to 775 nm and emits at 794 to 796 nm.
Fluorescent Dye  
Lung Cancer  
2
HY-109520 Glatiramer acetate
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression.
MHC  
Cancer   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
2
HY-P99931 Epcoritamab
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines.

Species: Human

CD3   CD20  
Chronic Lymphocytic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
2
HY-K6007 Basement Membrane Matrix for Organoid Culture

MCE Basement Membrane Matrix for Organoid Culture is primarily composed of natural basement membrane matrix extracted from mouse tumors. This product is mainly used for organoid culture.

Cell Biology 3D Cell Culture Basement Membrane Matrix

2
HY-K6008 Basement Membrane Matrix HC

MCE High-Concentration Basement Membrane Matrix (Phenol Red-Free) is primarily composed of natural basement membrane matrix extracted from mouse tumors. It is rich in extracellular matrix components and various naturally occurring growth factors, and is mainly used for the establishment of animal models and 3D tumor models.

Cell Biology 3D Cell Culture Basement Membrane Matrix

2
HY-K6011 Tumor Tissue Dissociation Solution

MCE Tumor Tissue Dissociation Solution is able to gently and efficiently dissociate tumor tissue samples into cell suspensions or cell aggregates, which can then be used for the subsequent construction of tumor organoids.

Cell Biology 3D Cell Culture Organoid Research

2
HY-D1905 ICG acid
ICG acid is a fluorescent dye used in medical diagnostics. ICG acid has absorption peaking at 800 nm and can absorb the near IR laser energy and release heat in the dyed tissue. ICG acid has been used in fluorescence-guided surgery to identify critical structures, including intra-abdominal tumors.
Fluorescent Dye  
Cancer  
1
HY-D1464A CH1055 triethylamine
CH1055 triethylamine is a near-infrared II (NIR-II) fluorescent dye that can be used as a fluorescent probe for in vivo imaging. CH1055 triethylamine can be conjugated with antibodies or ligands for specific imaging (for example the tumor imaging).
Fluorescent Dye  
Cancer  
1
HY-161541 Estradiol/BSA
Estradiol/BSA is the antigen-adjuvant conjugate formed by the coupling of Estradiol (HY-B0141) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
1
HY-N7755 Estradiol 3-glucuronide sodium
Estradiol 3-glucuronide sodium is an estrogen metabolite, which is a glucuronide conjugate formed by the catalysis of uridine diphosphate glucuronosyltransferase in tissues such as the liver from Estradiol (HY-B0141). Estradiol 3-glucuronide sodium is a potent substrate of Mrp2, with an S50 of 55.7 μM. Estradiol 3-glucuronide sodium achieves hepatobiliary transport in hepatocytes through basolateral uptake via OATP1B1, OATP1B3 and OATP2B1, as well as apical efflux via MRP2 and BCRP.
Endogenous Metabolite   ATP-binding cassette (ABC) transporters   OAT  
1
HY-P1783A M2e, human TFA
M2e, human TFA, consisting of the 23 extracellular residues of M2 (the third integral membrane protein of influenza A), has been remarkably conserved in all human influenza A. M2e, human TFA is a valid and versatile vaccine candidate to protect against any strain of human influenza A.
Influenza Virus  
Infection  
1
HY-12710 Rauwolscine
Rauwolscine is a selective α2-adrenoceptor antagonist that inhibits tumor growth and induces apoptosis.
Adrenergic Receptor  
Cancer   Depression   Pain   Alzheimer's Disease   Hypertension  
1
HY-D1464 CH1055
CH1055 is a near-infrared II (NIR-II) fluorescent dye that can be used as a fluorescent probe for in vivo imaging. CH1055 can be conjugated with antibodies or ligands for specific imaging (for example the tumor imaging).
Fluorescent Dye  
Cancer  
1
HY-W585842 Estradiol 3-glucuronide
Estradiol 3-glucuronide is an estrogen metabolite, which is a glucuronide conjugate formed from Estradiol (HY-B0141) via catalysis by uridine diphosphate glucuronosyltransferases in tissues such as the liver. Estradiol 3-glucuronide is a potent substrate of Mrp2, with an S50 value of 55.7 μM. Estradiol 3-glucuronide achieves hepatobiliary transport in hepatocytes through basolateral uptake via OATP1B1, OATP1B3 and OATP2B1, as well as apical efflux via MRP2 and BCRP.
Endogenous Metabolite   ATP-binding cassette (ABC) transporters   OAT  
1
HY-126855 Cholic acid 7-sulfate
Cholic acid 7-sulfate (7-Sulfocholic acid) is a selective agonist targeting TGR5 (EC50=0.17 μM) and a ligand for MHC class I-related protein (MR1). As a gut-restricted TGR5 agonist, cholic acid 7-sulfate binds to TGR5 on enteroendocrine L cells, induces GLP-1 secretion, and improves glucose tolerance in a TGR5-dependent manner. Cholic acid 7-sulfate also acts as an endogenous ligand for MR1, promoting the survival of mucosal-associated invariant T cells MAIT and the expression of homeostatic gene signatures, affecting MAIT cell development and function. Cholic acid 7-sulfate is mainly used in the research of diabetes and MAIT cell-related immune regulation.
G protein-coupled Bile Acid Receptor 1   MHC  
Glucose Metabolism   Obesity  
1
HY-P99634 Gatipotuzumab
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC).

Species: Human

Mucin  
Cancer  
1
HY-P99394 Talquetamab
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.

Species: Human

CD3  
Cancer  
1
HY-P99592 Solitomab
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer.

Species: Human

CD3  
Ovarian Cancer  
1
HY-P99033 Mosunetuzumab
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).

Species: Human

CD20   CD3  
Cancer Immunology   Non-Hodgkin Lymphoma  
1
HY-P99024 Glofitamab
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL).

Species: Human

CD20   CD3  
Cancer   Inflammation or Immune System Disease  
1
HY-P72257 Cellular tumor antigen P53/TP53, Human (His-SUMO)
The cellular tumor antigen P53/TP53 is a tumor suppressor that can induce growth arrest or apoptosis in a variety of tumor types. It regulates the cell cycle by negatively controlling genes critical for division. Cellular tumor antigen P53/TP53, Human (His-SUMO) is the recombinant human-derived Cellular tumor antigen P53/TP53, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

Species: Human; Source: E. coli

1
HY-P83697 6X His-tag Antibody (YA3432)
6X His-tag Antibody is a non-conjugated and Rabbit origined IgG monoclonal antibody, targeting to 6X His-tag.

Host: Rabbit; Reactivity: Species independent

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Tag Antibodies Primary Antibodies

1
HY-P80948B HA tag Antibody (YA3393)
Anti-HA tag Antibody is a non-conjugated and Rabbit origined IgG monoclonal antibody, targeting to HA tag.

Host: Rabbit; Reactivity: Species independent

Monoclonal Antibodies Recombinant Antibodies Tag Antibodies Primary Antibodies

1
HY-K6105 Human Gastric Cancer Organoid Kit

MCE Human Gastric Cancer Organoid Kit contains Gastric Cancer Organoid Basal Medium A, Gastric Cancer Organoid Supplement B (50×), Gastric Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human gastric cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

1
HY-D0992 PerCP
PerCP is a peridinin-chlorophyll protein complex derived from the dinoflagellate *Glenodinium*, suitable for immunofluorescence staining of formalin-fixed, paraffin-embedded human tumor sections. As a red fluorescent dye, PerCP enables clear differentiation between antibody-bound tumor regions and yellow-green autofluorescence of tissues. PerCP allows simultaneous observation of tissue morphology without counterstaining. PerCP can be used in cancer research (Ex/Em = 482/677 nm).
Fluorescent Dye  
Cancer  
/
HY-D2281 FAP Ligand 2
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging.
FAP  
/
HY-N10673 10α-Hydroxyepigambogic acid
10α-Hydroxyepigambogic acid can be extracted from Garcinia hanburyi. 10α-Hydroxyepigambogic acid can be used in the research of tumors.
Others  
Cancer  
/
HY-156087G Cholicamideβ (GMP)
Cholicamideβ (GMP) is a GMP grade of Cholicamideβ. Cholicamideβ (compound 6) is a self-assembling, small molecule, cancer vaccine adjuvant. Cholicamideβ can form virus-like particles with low cytotoxicity. Cholicamideβ, upon binding to peptide antigens, enhances antigen presentation by dendritic cells and induces antigen-specific T cells. Cholicamideβ can induce apoptosis and necrosis.
Apoptosis   Necroptosis  
/
HY-146579S Estrone-3-glucuronide-d4 lithium
Estrone-3-glucuronide-d4 lithium is the deuterium labeled Estrone-3-glucuronide lithium. Estrone 3-glucuronide is a dominant urinary metabolite of?Estradiol?(HY-B0141) and urinary marker for female fertile window prediction. Estrone 3-glucuronide can be used in combination with luteinizing hormone in ovulation prediction kits.
Isotope-Labeled Compounds   Endogenous Metabolite   Drug Metabolite  
Metabolic or Endocrine Disease  
/
HY-160261S EP300/CBP-IN-2
EP300/CBP-IN-2 is a potent EP300/CBP inhibitor that has good activity in vivo. EP300/CBP-IN-2 can be used for the research of cancer.
Histone Acetyltransferase   Epigenetic Reader Domain  
Cancer  
/
HY-P5471 Melan-A/MART-1 analog
Melan-A/MART-1 analog ([Leu27]-Melan-A, MART-1 (26-35)) is a biological active peptide. (This Melan-A (26-35) analog, Leu substituted for Ala at position 27, shows better HLA-A*0201 binding properties as well as better immunogenicity and antigenicity than the natural Melan-A (26-35).Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
Others  
/
HY-163587 PRMT5-IN-39-d3
PRMT5-IN-39-d3 is the deuterated form of PRMT5-IN-39. PRMT5-IN-39-d3 is an orally active PRMT5 inhibitor and can be used for study of cancer.
Histone Methyltransferase  
Cancer  
/
HY-P4229 C-Peptide (human)-[Val7.10-d16]
([D8]Val7,10)-C-Peptide (human) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.
Isotope-Labeled Compounds  
/
HY-N21965 Thesinine
Thesinine is a saturated pyrrolizidine alkaloid isolated from the seeds and flowers of *Borago officinalis*; it is the primary alkaloid in borage seeds and the only alkaloid present in borage flowers. In silico predictions indicate that Thesinine binds to the AKT1, MAPK3, MMP9, and MAPK14 proteins. Thesinine is applicable to research related to skin aging
Akt   p38 MAPK   MMP  
Cellular Senescence  
/
HY-N19739 Efrapeptin F
Efrapeptin F is a mitochondrial complex V inhibitor and cytotoxic agent with in vivo antitumor activity. Efrapeptin F induces cell death in glucose-limiting conditions, with preferential cytotoxicity to nutrient-deprived cancer cells under hypoxic conditions. Efrapeptin F can be used for the research of pancreatic cancer, prostate cancer, breast cancer, central nervous system cancer, colon cancer, lung cancer, melanoma, ovarian cancer, kidney cancer, stomach cancer.

Source: Tolypocladium fungi

Mitochondrial Metabolism  
Cancer  
/
HY-P991292 AB-3A4
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

ADC Antibodies  
Cancer  
/
HY-N18236 3β-Acetoxyl-atractylenolide I
3β-Acetoxyl-atractylenolide I is a LSD1 inhibitor with an IC50 of 57 μM. 3β-Acetoxyl-atractylenolide I blocks tumor growth, metastasis and invasion. 3β-Acetoxyl-atractylenolide I is used in the research of various cancers including prostate cancer, breast cancer, neuroblastoma, gastric cancer, colon cancer, bladder cancer, esophageal cancer, acute myeloid leukemia and retinoblastoma.
Histone Demethylase  
Breast Cancer   Prostate Cancer   Gastric Cancer   Bladder Cancer   Acute Myeloid Leukemia   Esophageal Cancer  
/
HY-161581 Metronidazole/OVA
Metronidazole/OVA is a conjugate of Metronidazole (HY-B0318) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-161544 Cholyglycine/BSA
Cholyglycine/BSA is a conjugate of Cholyglycine and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-D3432 WazaGaY-1
WazaGaY-1 is an aza-BODIPY derivative, functions as a NIR-I/NIR-II fluorescent contrast agent. WazaGaY-1 undergoes internalization into tumor cells predominantly via clathrin-coated pits. WazaGaY-1 can be used for the research of glioblastoma, ovarian carcinoma and melanoma (Ex/Em = 685/820 nm).
Fluorescent Dye  
Ovarian Cancer   Cancer Immunology   Immunotherapy for Melanoma   Glioblastoma  
/
HY-158279 Gentamicin/OVA
Gentamicin/OVA is an antigen-adjuvant conjugate conjugate of Gentamicin (HY-A0276A) and ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the production of antigen-specific T cells.
Antibiotic   Bacterial  
Inflammation or Immune System Disease  
/
HY-P990814 Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34)
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) reacts with the receptor binding domain (RBD) epitope B in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) can be used for the research of SARS-CoV-2 infection.

Species: Virus

SARS-CoV  
SARS-CoV-2 Infection  
/
HY-D3182 AldRed 588-A
AldeRed 588-A is a fluorescent labeling reagent and a substrate for aldehyde dehydrogenase (ALDH). AldeRed 588-A is metabolized by functionally active ALDH enzymes, thereby specifically labeling viable ALDHbright cell populations with red-shifted fluorescence. AldeRed 588-A supports one-step isolation and sorting of ALDH-expressing cells (including normal stem cells and cancer stem cells), and can be used in combination with green fluorophores for multicolor experimental applications. AldeRed 588-A is widely applicable to research related to various cancers such as bladder cancer, breast cancer, and head and neck cancer.
Fluorescent Dye   Aldehyde Dehydrogenase (ALDH)  
Cancer  
/
HY-P3129 KRAS G13D peptide, 25 mer
KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine.
Ras  
Cancer   Inflammation or Immune System Disease  
/
HY-P992400 Lu AF87908
Lu AF87908 is an IgG1 monoclonal antibody targeting the p-Ser396/404 epitope of tau protein, which mainly binds to the pSer396 region. Lu AF87908 can be used in the research of Alzheimer's disease. The recommended isotype control is human IgG1 kappa (HY-P99001).

Species: Human

Tau Protein  
Alzheimer's Disease  
/
HY-159672 3D-Monophosphoryl Lipid (12,16)
3D-Monophosphoryl Lipid (12,16) (3D-MPL (12,16)) is a TLR4 agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-D2309 IRDye700Dx (Maleimide)
IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in HER2-positive breast cancer cells without causing damage to HER2-negative breast cancer cells.
Fluorescent Dye   Photosensitizer  
HER-2 Positive Breast Cancer  
/
HY-P4473S H-Phe-Ile-OH-13C6,15N TFA
H-Phe-Ile-OH-13C6,15N TFA is the 13C- and 15N-labeled H-Phe-Ile-OH (HY-P4473). H-Phe-Ile-OH is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.
Isotope-Labeled Compounds  
/
HY-D3185 AlDeSense AM
AlDeSense AM is a cell-permeable ALDH1A1-selective fluorescent reporter. AlDeSense AM is oxidized by ALDH1A1, which eliminates photoinduced electron transfer quenching and enhances the fluorescent signal. AlDeSense AM can be used to detect cells with cancer stem cell properties, as well as to monitor the plasticity of cancer stem cells in cell culture systems and animal models. AlDeSense AM is applicable to the study of cancers associated with cancer stem cells, including chronic myeloid leukemia, melanoma, and breast cancer.
Fluorescent Dye   Aldehyde Dehydrogenase (ALDH)  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-P1826A CLIP (86-100) TFA
CLIP (86-100) TFA is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP). CLIP is a small self-peptide and cleavage product of the invariant chain that resides in the HLA-II antigen binding groove and is believed to play a critical role in the assembly and transport of MHC class II alphabetaIi complexes through its interaction with the class II peptide-binding site.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-14249S1 (R)-Bicalutamide-d5
(R)-Bicalutamide-d5 is deuterated labeled (R)-Bicalutamide (HY-108250). (R)-Bicalutamide is an androgen receptor (AR) antagonist, with antineoplastic activity. (R)-Bicalutamide is widely used for the research of prostate cancer.
Androgen Receptor   Autophagy   Isotope-Labeled Compounds  
Cancer  
/
HY-P3248 J5 peptide
J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP85-99 to HLA-DR2. J5 peptide alleviates PLP139-151/MBP85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-113157 Estrone 3-glucuronide
Estrone 3-glucuronide is a dominant urinary metabolite of Estradiol (HY-B0141) and urinary marker for female fertile window prediction. Estrone 3-glucuronide can be used in combination with luteinizing hormone in ovulation prediction kits
Drug Metabolite   Endogenous Metabolite  
Female Reproductive System Disease  
/
HY-P992374 huDMB5F3
huDMB5F3 (DMB5F3; chDMB5F3) is a human monoclonal antibody against human CD227/MUC1, with a Ka value of 5.89 pM for its human target. huDMB5F3 enters MUC1-positive cancer cells via a temperature-dependent internalization process. huDMB5F3 induces cytotoxicity in MUC1-positive cancer cells. huDMB5F3 can be used in the research of various cancers including breast cancer, pancreatic cancer and gastric cancer.

Species: Human

Mucin  
Breast Cancer   Gastric Cancer   Pancreatic Cancer  
/
HY-W008449S2 1-Methylxanthine-d3
1-Methylxanthine-d3 is deuterated labeled 1-Methylxanthine (HY-W008449). 1-Methylxanthine, a caffeine derivative, is an essential human urinary metabolite of caffeine and theophylline (1,3-dimethylxanthine, TP). 1-Methylxanthine enhances the radiosensitivity of tumor cells.
Drug Metabolite   Endogenous Metabolite   Isotope-Labeled Compounds  
/
HY-180885S KRAS G12D-IN-35
KRAS G12D-IN-35 (example 7) is a potent and orally active KRAS G12D inhibitor. KRAS G12D-IN-35 suppresses p-ERK in AGS cells and potently inhibits the proliferation of various KRAS G12D-mutant cancer cell lines. KRAS G12D-IN-35 inhibits tumor growth in HPAC and GP2D mouse models. KRAS G12D-IN-35 can be used for cancer research, such as pancreatic and colorectal cancer.
Ras   ERK  
Colorectal Cancer   Pancreatic Cancer  
/
HY-N16024 FP-20 sodium
FP-20 sodium, a selective TLR4 agonist, is a vaccine adjuvant. FP-20 sodium induces MAPK- and NLRP3-dependent inflammasome activation. FP20 shows no toxicity in mouse vaccination experiments with OVA antigen and induces IgG production.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-170905S MAT2A-IN-22
MAT2A-IN-22 (Compound 29-1) is a BBB-penetrable and orally active MAT2A inhibitor with an IC50 of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects.
Methionine Adenosyltransferase (MAT)   Isotope-Labeled Compounds  
Cancer  
/
HY-P10662 HLA-B*0801-binding EBV peptide
HLA-B*0801-binding EBV peptide is an Epstein-Barr virus (EBV) epitope FLRGRAYGL. HLA-B*0801-binding EBV peptide can bind to the HLA-B*0801 molecule. HLA-B*0801-binding EBV peptide can be presented to CD8+ T cells through HLA-B*0801 to activate a specific immune response.
MHC  
Infection   Inflammation or Immune System Disease  
/
HY-N15588 Smyrindiol
Smyrindiol is a compound found in Dorstenia turbinate. Smyrindiol exerts anti-inflammatory and antimicrobial activities by inhibiting the secretion of tumor-associated proteases (MMP-2). Smyrindiol can be used in the study of brain tumors such as glioblastoma.
MMP  
Cancer  
/
HY-P10790 Breast cancer targeting peptide 18–4
Breast cancer targeting peptide 18–4 is a KRT1 receptor-targeting peptide, with a Kd of 0.98 μM. The amino acid sequence of Breast cancer targeting peptide 18–4 is WxEAAYQrFL, and it is an analogue of P160 peptide (HY-P10789). When covalently conjugated with the anticancer peptide MccJ25, Breast cancer targeting peptide 18–4 significantly increases the cellular uptake of MccJ25 in breast cancer cells and enhances its anticancer activity. The covalent conjugate exhibits IC50 values of 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR cells, respectively.
Microtubule/Tubulin  
/
HY-153209G Adjuvant-4 (GMP)
Adjuvant-4 (GMP) is a GMP grade Adjuvant-4. Adjuvant-4 is a vaccine adjuvant that enhances antigen-specific antibody titers and cytotoxic T lymphocyte (CTL) responses. Adjuvant is generally an oil-in-water emulsifier of mineral oil and mannitol monooleate.
Biochemical Assay Reagents  
/
HY-B1729S1 Phenoxyethanol-d4
Phenoxyethanol-d4 is the deuterium labeled Phenoxyethanol. Phenoxyethanol has a broad spectrum of antimicrobial agent. Phenoxyethanol is an uncouple agent in oxidative phosphorylation from respiration and competitively inhibits malate dehydrogenase. Phenoxyethanol is used as a preservative in cosmetic, vaccine, and textile, et al.
Isotope-Labeled Compounds   Oxidative Phosphorylation   Bacterial   Fungal  
Infection  
/
HY-112251GL D-Lin-MC3-DMA (GMP Like)
D-Lin-MC3-DMA (GMP Like) is the GMP Like class D-Lin-MC3-DMA (HY-112251). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. D-Lin-MC3-DMA, an ionizable cationic lipid, is a potent siRNA delivery vehicle.
Liposome  
Cancer  
/
HY-P10686 CH401 peptide
CH401 peptide is a HER2-derived antigen peptide. After being bound to the artificial viral capsid by a self-assembled β-cyclic peptide, CH401 peptide is encapsulated in a lipid bilayer containing the lipid adjuvant α-GalCer, and can be studied as a self-adjuvant anti-breast cancer vaccine candidate.
EGFR  
Cancer  
/
HY-P990815 Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01)
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to SARS-CoV-2 S protein. Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) reacts with the receptor binding domain (RBD) epitope A in the spike (S) protein of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can block the binding of the SARS-CoV-2 S protein to angiotensin-converting enzyme 2 (ACE2). Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) can be used for the research of SARS-CoV-2 infection.

Species: Virus

SARS-CoV  
SARS-CoV-2 Infection  
/
HY-P5078 NPNA hexamer
NPNA hexamer is a peptide. NPNA hexamer can be used for the research of malaria and the development of a sporozoite vaccine.
Others  
Infection  
/
HY-D2285 MOR-CES2
MOR-CES2 is a near-infrared fluorescent probe (Ex= 630 nm, Em=735 nm) capable of identifying cancer cells and tissues, as well as exhibiting a sensitive response to inflammation. MOR-CES2 holds potential as an efficient imaging tool in assisting surgical resection of CES2-related tumors.
Fluorescent Dye  
/
HY-P991378 MORAb-066
MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research.

Species: Human

Transmembrane Glycoprotein  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-P992388 IO-108
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors.

Species: Human

LILRB  
Cancer  
/
HY-P992441 PHST001
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer.

Species: Human

Transmembrane Glycoprotein  
Ovarian Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer  
/
HY-B1729S Phenoxyethanol-d2
Phenoxyethanol-d2 is the deuterium labeled Phenoxyethanol. Phenoxyethanol has a broad spectrum of antimicrobial agent. Phenoxyethanol is an uncouple agent in oxidative phosphorylation from respiration and competitively inhibits malate dehydrogenase. Phenoxyethanol is used as a preservative in cosmetic, vaccine, and textile, et al.
Isotope-Labeled Compounds   Oxidative Phosphorylation   Bacterial   Fungal  
Infection  
/
HY-P992097 Fanolesomab
Fanolesomab is an anti-human CD15-targeting monoclonal antibody. Fanolesomab binds to the CD15 epitope on white blood cells to enable imaging of white blood cell distribution, migration, and infection sites. Fanolesomab can be used for the research of infection.

Species: Human

Transmembrane Glycoprotein  
Infection  
/
HY-105129AS Pimonidazole-d10
Pimonidazole-d10 is the deuterium labeled Pimonidazole. Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor. Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .
Isotope-Labeled Compounds  
/
HY-P991954 GT103
GT103 is a human-derived monoclonal antibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer.

Species: Human

Complement System   Syk  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-P991417 LYN00101
LYN00101 is a human monoclonal antibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research.

Species: Human

VEGFR  
Cancer  
/
HY-P1881 HPV16-E711-20 epitope
HPV16-E711-20 epitope is a well-known HLA-A*0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine.
HPV  
Cancer  
/
HY-163591 PRMT5-IN-36-d3
PRMT5-IN-36-d3 is the deuterated derivative of PRMT5-IN-36. PRMT5-IN-36-d3 (compound 4) is an orally active PRMT5 inhibitor for cancer research.
Histone Methyltransferase  
Cancer  
/
HY-122878 HS-131
HS-131, a near infrared dye tethered Hsp90 inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers.
HSP  
/
HY-P11059 MC38 SLP Reps1
MC38 SLP Reps1 is a peptide neoantigen generated by mutation of the MC38 colon cancer cell line and can be used for the synthesis of nanoparticle vaccines.
Others  
/
HY-151580S CDK2-IN-14-d3
CDK2-IN-14-d3 is a potent and selective CDK2 inhibitor. CDK2-IN-14-d3 can be used in research of cancer.
CDK  
Cancer  
/
HY-106204 Nelipepimut-S
Nelipepimut-S (E75) is a peptide vaccine targeting HER2. When used in combination with granulocyte-macrophage colony-stimulating factor, Nelipepimut-S stimulates immune activity and induces anti-HER2 immune responses. Nelipepimut-S can be used in research related to breast cancer, triple-negative breast cancer and ductal carcinoma in situ.
EGFR  
Triple-Negative Breast Cancer  
/
HY-P992352 ES005
ES005 is an anti-tumor compound and LAG3 inhibitor. ES005 blocks the interactions of LAG3 with MHC-II, LSECtin and FGL1, thereby effectively reversing the LAG3-mediated inhibition of T cell activation and NFAT reporter gene expression. ES005 exhibits significant tumor growth inhibitory effects in syngeneic mouse breast tumor models using humanized LAG3 knock-in mice. ES005 can be used for breast tumor-related research.

Species: Human

/
HY-P10339 SMCY peptide
SMCY peptide inhibits the binding of iodinated standard peptide to HLA-B7 with an IC50 of 34 nM. As an epitope of the H-Y antigen, SMCY peptide can be presented by the HLA-B7 molecule and recognized by specific T cells, leading to transplant rejection.
Others  
Inflammation or Immune System Disease  
/
HY-P991583 GP369
GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer.

Species: Human

FGFR   ERK  
Cancer  
/
HY-P992510 Sofetabart
Sofetabart (LY-4170156 Antibody) is a humanized IgG1 antibody that specifically targets folate receptor α (FRα). Sofetabart can be used to synthesize the antibody-drug conjugate (ADC) Sofetabart mipitecan. Sofetabart is applicable to research related to advanced ovarian cancer, platinum-resistant epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, as well as platinum-sensitive ovarian cancer.

Species: Human

ADC Antibodies   Folate Receptor (FR)  
Ovarian Cancer  
/
HY-160198G Vaccine adjuvant-1 (GMP)
Vaccine adjuvant-1 GMP is Vaccine adjuvant-1 produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Vaccine adjuvant-1 is an vaccine adjuvant is a vaccine adjuvant containing an oil phase, emulsifying agent and water.
Others  
Infection  
/
HY-W248121 Pyrromethene 567
Pyrromethene 567 is a commercially available BODIPY dye with a photodynamic cytotoxicity IC50 of 6.8 ± 1.8 μM.Pyrromethene 567 shows cytoplasmic localization and limited cellular uptake in cancer cells.Pyrromethene 567 can be used for the research of lung cancer.
Fluorescent Dye  
Lung Cancer  
/
HY-159671 3D-Monophosphoryl Lipid (14)
3D-Monophosphoryl Lipid (14) (3D-Monophosphoryl Lipid (14)) is a TLR4 agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines.
Toll-like Receptor (TLR)  
Inflammation or Immune System Disease  
/
HY-P991741 Anti-HCMV gB Antibody (SM5-1)
Anti-HCMV gB Antibody (SM5-1) is an efficient neutralizing human monoclonal antibody that targets the human cytomegalovirus (HCMV) glycoprotein B (gB). Anti-HCMV gB Antibody (SM5-1) neutralizes HCMV by blocking the conformational changes of gB and interfering with its binding to the gH/gL complex. Anti-HCMV gB Antibody (SM5-1) can broadly neutralize different virus strains and inhibit the infection of various cell types (such as fibroblasts, epithelial cells, and dendritic cells). Anti-HCMV gB Antibody (SM5-1) can be used in HCMV vaccine research.

Species: Virus

CMV  
Cytomegalovirus Infection  
/
HY-149413 FHND5071
FHND5071 is a potent and selective RET kinase inhibitor, FHND5071 can exert antitumor effects by inhibiting RET autophosphorylation. FHND5071 can be used for tumor diseases research.
RET  
Cancer  
/
HY-P991958 GIGA-564
GIGA-564 is a fully human anti-CTLA4 IgG1 monoclonal antibody with a Kd of 9.8 nM. GIGA-564 binds to a unique epitope of CTLA-4, mediates FcR-dependent signaling pathways, depletes CTLA-4-highly-expressing regulatory T cells within tumors, and inhibits the proliferation of peripheral regulatory T cells. GIGA-564 exhibits anti-tumor activity in mouse models. GIGA-564 can be used for tumor research.

Species: Human

CTLA-4  
Cancer  
/
HY-N15176 Bisucaberin
Bisucaberin is a natural siderophore, is a DNA synthesis inhibitor. Bisucaberin shows cytostasis for tumor cells. Bisucaberin sensitizes tumor cells to macrophage-mediated cytolysis.

Source: Alteromonas haloplanktis Strain SB-1123

DNA/RNA Synthesis  
/
HY-B0109AS Dorzolamide-d3 hydrochloride
Dorzolamide-d3 hydrochloride is deuterated labeled Dorzolamide hydrochloride (HY-B0109A). Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
Carbonic Anhydrase   Isotope-Labeled Compounds  
/
HY-B1455S Clindamycin-d3 hydrochloride
Clindamycin-d3 (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria.
Bacterial   Antibiotic   Parasite  
/
HY-P99856 Docaravimab
Docaravimab is an antibody, targeting ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III. Docaravimab can be used in research of Rabies.

Species: Rabies lyssavirus

RABV  
Infection  
/
HY-P992111 Elfritatug
Elfritatug (UCB4594) is a humanized monoclonal antibody targeting human leukocyte antigen-G (HLA-G). By binding to HLA-G on the surface of tumor cells, Elfritatug blocks its immunosuppressive effect, thereby enhancing the body's immune response against tumors.

Species: Human

MHC  
Cancer  
/
HY-P11060 MC38 SLP Adpgk
MC38 SLP Adpgk (Adpgk peptide) is an H-2 Kb-restricted colorectal cancer neoantigen peptide. MC38 SLP Adpgk is formulated into PCNP nanocomplexes together with CpG ODN. PCNP vaccines significantly enhance the co-delivery efficiency of neoantigens and adjuvants to lymphoid organs, and activate cytotoxic T cells. PCNP vaccines not only protect mice from MC-38 colorectal tumor invasion, but also exhibit anti-tumor efficacy in established colorectal tumor models and significantly prolong the survival of tumor-bearing mice.
MHC  
Colorectal Cancer  
/
HY-B1455S1 Clindamycin-13C,d3
Clindamycin-13C,d3 is the 13C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria.
Isotope-Labeled Compounds   Bacterial   Antibiotic   Parasite  
/
HY-161552 T3/BSA
T3/BSA is an antigen-adjuvant conjugate of T3 (thyroid hormone) and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-119846 Afromosin
Afromosin is an isoflavone, that can be isolated from Millettia dielsiana Harms. Afromosin exhibits remarkable tumor inhibitory effects.
Others  
/
HY-161566 DHT/BSA
DHT/BSA is an antigen-adjuvant conjugate formed by the coupling of DHT (dihydrotestosterone) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-183033 ABC transporter modulator-2
ABC transporter modulator-2 (Compound I-200) is a ABC transporter expression modulator. ABC transporter modulator-2 upregulates the expression of wild-type ABCC6 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of wild-type ABCB4 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of wild-type ABCD2 with an EC50 of <1 μM. ABC transporter modulator-2 upregulates the expression of the ABCA4P1380L mutant with an EC50 of <1 μM. ABC transporter modulator-2 can be used in the research of diseases associated with ABC transporter dysfunction.
ATP-binding cassette (ABC) transporters  
Metabolic or Endocrine Disease  
/
HY-P990716 Sabestomig
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma.

Species: Human

PD-1/PD-L1   Tim3  
Inflammation or Immune System Disease  
/
HY-183032 ABC transporter modulator-1
ABC transporter modulator-1 (Compound I-5) is an ABC transporter expression enhancer. ABCC6 modulator-1 upregulates the expression of wild-type ABCC6, wild-type ABCB4, and ABCA4P1380L mutant, with an EC50 of <1 μM for all.
ATP-binding cassette (ABC) transporters  
Metabolic or Endocrine Disease  
/
HY-183034 ABC transporter modulator-3
ABCC6 modulator-3 (Compound I-71) is a ABCC6 activator with an EC50 < 1 μM. ABCC6 modulator-3 upregulates the expression of wild-type ABCC6. ABCC6 modulator-3 is used in research on diseases associated with ABC transporter dysfunction.
ATP-binding cassette (ABC) transporters  
Metabolic or Endocrine Disease  
/
HY-N11630 Pinellic acid
Pinellic acid is an orally active adjuvant for intranasal influenza vaccines. Pinellic acid can be extracted from the tubers of Pinellia ternata Breitenbach. When administered intranasally in combination with influenza HA vaccine, Pinellic acid slightly increases the titers of antiviral IgG antibodies in bronchoalveolar lavage fluid and serum. Pinellic acid shows no hemolytic activity. Pinellic acid can be used in studies related to influenza virus infection.
Influenza Virus   Biochemical Assay Reagents  
Influenza Virus Infection  
/
HY-173230 ABCA1 inducer 2
ABCA1 inducer 2 is a non-lipotropic ABCA1 inducer. ABCA1 inducer 2 upregulates the expression of ABCA1 by targeting the LXR pathway. ABCA1 inducer 2 can reduce ox-LDL-induced lipid accumulation and thus inhibit foam cell formation. ABCA1 inducer 2 has anti-atherosclerotic potential.
ATP-binding cassette (ABC) transporters   LXR  
Blood or Cardio-cerebrovascular Disease  
/
HY-N2216 Polygalasaponin XXXI
Polygalasaponin XXXI (Onjisaponin F) is an effective adjuvant for intranasal administration of influenza Influenza hemagglutinin (HA) vaccine to protect influenza virus infection.
Influenza Virus  
/
HY-137307 Cholest-5-ene-3ß,22(S)-diol
Cholest-5-ene-3ß,22(S)-diol ((22S)-Hydroxycholesterol) is an orally active oxysterol with no significant cytotoxic, oxidative, or inflammatory effects on human prokaryotic leukemia cells. Cholest-5-ene-3ß,22(S)-diol inhibits weight gain and increased serum triacylglycerol (TAG) levels in rat models.
LXR   ATP-binding cassette (ABC) transporters  
Inflammation or Immune System Disease  
/
HY-N9517 QS 7
QS 7 (QS 7 Api) is a triterpene saponin found in the bark of Quillaja saponaria and immune adjuvant with immune response potentiator activity. QS 7 can be used as vaccine adjuvant for the research of antitumor and antiviral vaccine development.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-176785S MCB-294
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
Ras   Apoptosis   p38 MAPK   Caspase   TNF Receptor  
/
HY-161560 Tacrolimus/BSA
Tacrolimus/BSA is the antigen-adjuvant conjugate formed by the conjugation of Tacrolimus (HY-13756) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P3486 GADGVGKSAL
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P3487 GAGGVGKSA
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-W010649 Isoxazole
Isoxazole is a member of the five-membered heterocycle drug scaffold. Isoxazole has been used as a BET bromodomain inhibitor and can improve β-cell function in a diabetic mouse model. Isoxazole and its derivatives exhibit broad biological activities (such as antimicrobial, antibacterial, antifungal, antiviral, anticancer, anti-inflammatory, immunomodulatory, analgesic, anti-tuberculosis, and anti-diabetic effects). For example, the bicyclic Isoxazole can act as an HSP90 inhibitor, and the tricyclic Isoxazole is promising as a selective multidrug resistance protein (MRP1) inhibitor​.
HSP   Epigenetic Reader Domain   ATP-binding cassette (ABC) transporters   Bacterial   Fungal   Antibiotic  
Inflammation or Immune System Disease   Leukemia/Lymphoma/Myeloma   Fungal Infection   Glucose Metabolism   Mycobacterium Tuberculosis Infection  
/
HY-Y1097S Monomethyl phthalate-d4
Monomethyl phthalate-d4 (2-(Methoxycarbonyl)benzoic acid-d4) is the deuterium labeled Monomethyl phthalate. Monomethyl phthalate is a phthalate metabolite. Monomethyl phthalate acts as a urinary biomarker of phthalates exposure and can be used as a standard for the determination of thyroid cancer and benign nodule.
Isotope-Labeled Compounds  
Cancer  
/
HY-W674245 10-Hydroxyhexadecanoic acid
10-Hydroxyhexadecanoic acid is a hydroxy fatty acid found in Camembert cheese. 10-Hydroxyhexadecanoic acid can promote cholesterol efflux from ABCA1 and ABCG1, preventing the accumulation of excess cholesterol in cells. 10-Hydroxyhexadecanoic acid can be used in anti-atherosclerosis research.
ATP-binding cassette (ABC) transporters  
Blood or Cardio-cerebrovascular Disease  
/
HY-P3488 GADGVGKSA
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P3051 CKS-17
CKS-17 is a synthetic retroviral envelope peptide. CKS-17 has the highly conserved amino acid sequences occurring within the transmembrane envelope protein of many animal and human retroviruses. CKS-17 acts as an immunomodulatory epitope and exhibits suppressive properties for numerous immune functions.
Reverse Transcriptase  
Inflammation or Immune System Disease  
/
HY-161533 Digoxin/BSA
Digoxin/BSA is an antigen-adjuvant conjugate of Digoxin (HY-B1049) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-101092B QS-21-Xyl
QS-21-Xyl is a active component of QS-21 (HY-101092A). QS-21 is a natural vaccine adjuvant and induces a balanced Th1/Th2 immune response, particularly cellular immunity.
Drug Intermediate  
Cancer   Inflammation or Immune System Disease  
/
HY-100978 (±)-Hexanoylcarnitine chloride
(±)-Hexanoylcarnitine chloride is a fatty acid metabolite that breaks down fatty acids into energy that can be used by the body. (±)-Hexanoylcarnitine chloride also serves as a specific and easily detectable biomarker for rat skeletal muscle toxicity. Cerivastatin (HY-129458) and TMPD (HY-W012145) induce an increase in Hexanoylcarnitine in rats in a metabolomic analysis of the rectus femoris muscle. In type 2 diabetes, Hexanoylcarnitine is also significantly associated with and improves prediction of all-cause mortality. Hexanoylcarnitine is a biomarker for the identification of novel pathogenic pathways.
Endogenous Metabolite  
Glucose Metabolism  
/
HY-12678S1 Entrectinib-d8
Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC50 values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice.
Isotope-Labeled Compounds   Trk Receptor   Anaplastic lymphoma kinase (ALK)   Autophagy   ROS Kinase  
/
HY-P5470 LMP2A (426-434)
LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A*02 subtypes (A*02:01, A*02:03, A*02:06 and A*02:07). LMP2A (426-434) can induce a strong IFN-γ secretion response, stimulating the production of a high proportion of CD8+ IFN-γ+ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .
EBV   IFNAR  
Infection   Autoimmune Disease  
/
HY-P2514 TET 830 modified/T-helper epitope from tetanus toxoid
TET 830 modified/T-helper epitope from tetanus toxoid is a modified T-helper epitope from tetanus toxoid. TET 830 modified/T-helper epitope from tetanus toxoid induces T-cells responses and is used as a helper peptide in vaccinations.
Others  
Inflammation or Immune System Disease  
/
HY-161543 DHT/KLH
DHT/KLH is a conjugate of DHT (dihydrotestosterone) and keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt linear epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P6312 ESAT6 Epitope
ESAT6 Epitope is a ESAT6 CD4+ T cell epitope. ESAT6 Epitope binds to MHC class I molecules with an IC50 value of approximately 180 nM. ESAT6 Epitope has weak immunogenicity. ESAT6 Epitope can be used in studies related to pulmonary tuberculosis.
MHC  
Tuberculosis  
/
HY-N1464A Aristolone
Aristolone is a sesquiterpene that can be isolated from Aristolochia debilis, Rosmarinus officinalis and Ficus Auriculata. Aristolone in Ara Fruit can be used as a prediction of apoptosis in HeLa cells. Aristolone inhibits the C1 complement component. Aristolone produces cytotoxicity effects on cells. Aristolone has anticancer properties and can be studied in research for cervical cancer.
Complement System   Apoptosis  
Cancer   Digestive System Disease   Autoimmune Disease   Digestive System Inflammation  
/
HY-P11058 OVA(250-264)
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
MHC  
/
HY-101092A QS-21
QS-21 is a mixture of QS-21-Xyl (HY-101092B) and QS-21-Api (HY-101092), with a ratio of 35:65. QS-21 is an innate immune system-targeted adjuvant. QS-21 is promising for research of oncology vaccines (e.g., melanoma) and infectious disease vaccines (e.g., HIV, malaria).
Toll-like Receptor (TLR)  
Cancer   Infection  
/
HY-P11303 PADRE peptide
PADRE peptide is a pan-HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4+ T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7-specific CD8+ T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C). The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA. PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer.
CD74   MHC  
Cervical Cancer   Glioblastoma  
/
HY-P2527 Tyrosinase-related Protein 2 (TRP-2) (181-188)
Tyrosinase-related Protein 2 (TRP-2) (181-188) is a tyrosinase-related protein 2 (TRP-2)-derived peptide, corresponding to residues 180-188. Tyrosinase-related Protein 2 (TRP-2) (181-188) is the major reactive epitope within TRP-2 recognized by anti-B16 CTLs. Tyrosinase-related Protein 2 (TRP-2) (181-188) is a peptide conforming to the MHC class I H2-Kb binding motif.
Tyrosinase  
Inflammation or Immune System Disease  
/
HY-153235 COVID-19 Spike Protein mRNA-LNP
COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein. COVID-19 Spike Protein undertakes the functions of virus binding with host cell receptors, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design. COVID-19 Spike Protein mRNA-LNP can be used for RNA delivery, vaccine formulation and design targeting SARS-CoV-2.
mRNA   SARS-CoV   Liposome  
Infection  
/
HY-D0226 Quinizarin
Quinizarin (1,4-Dihydroxyanthraquinone), a part of the anticancer agents such as Doxorubicin, Daunorubicin, and Adriamycin, interacts with DNA by intercalating mode (Kd=86.1 μM). Quinizarin is used as a fungicide and pesticide chemical and has shown the ability to inhibit tumor cell growth.
DNA/RNA Synthesis   Fungal  
Cancer   Infection  
/
HY-P5089A Enterotoxin STp (E. coli) TFA
Enterotoxin STp (E. coli) TFA is a heat-stable enterotoxin that can be used in vaccine research.
Biochemical Assay Reagents  
Infection  
/
HY-P1826 CLIP (86-100)
CLIP (86-100) is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP). CLIP is a small self-peptide and cleavage product of the invariant chain that resides in the HLA-II antigen binding groove and is believed to play a critical role in the assembly and transport of MHC class II alphabetaIi complexes through its interaction with the class II peptide-binding site.
CD74  
Cancer   Inflammation or Immune System Disease  
/
HY-N2108 7-Ethylcamptothecin
7-Ethylcamptothecin is a derivative of Camptothecin (HY-16560) and a DNA topoisomerase I inhibitor that exhibits significant antitumor activity against tumor cells. 7-Ethylcamptothecin serves as a key precursor for the synthesis of 20 (S)-O-substituted benzoyl-7-ethylcamptothecin compounds. 7-Ethylcamptothecin is widely used in various tumor-related scientific studies.
Drug Derivative   Drug Intermediate   Topoisomerase  
Cancer  
/
HY-P990717 Brenetafusp
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3+ T cells to kill PRAME+ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer.

Species: Human

CD3  
Cancer  
/
HY-P2695 STh
STh, an Escherichia coli heat-stable toxin, is a 19 amino acid polypeptide encompassing three disulfide bridges. STh is an antigen of interest in the search for a broad coverage enterotoxigenic Escherichia coli (ETEC) vaccine.
Others  
Infection  
/
HY-161553 Biotin/KLH
Biotin/KLH is an antigen-adjuvant conjugate that consists of Biotin and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P10554 Myhc-α(334–352)
Myhc-α(334–352) is a sequence fragment of amino acid residues 334 to 352 of cardiac myosin heavy chain α. Myhc-α(334–352) is an immunodominant epitope that can induce autoimmune reactions in A/J mice, leading to the occurrence of myocarditis. Myhc-α(334–352) can be used to study the autoimmune pathways of myocarditis and dilated cardiomyopathy.
Others  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P1827 mTRP-2 (180-188)
mTRP-2 (180-188) is an MHC class I-restricted tumor-associated antigenic peptide derived from mouse tyrosinase-related protein 2 (TRP-2). mTRP-2 (180-188) binds to HLA-A*0201 with an ID50 of 36 nM. mTRP-2 (180-188) can be presented by H-2Kb molecules and activate TRP-2-specific cytotoxic T lymphocytes (CTL). mTRP-2 (180-188) induces immune responses against B16 melanoma by promoting antigen-specific T cell proliferation, cytokine release, and CTL-mediated tumor cell killing. mTRP-2 (180-188) can be used in studies related to melanoma, glioma, and tumor immunology.
Tyrosinase   MHC  
Melanoma  
/
HY-13442AS Eribulin-d3 mesylate
Eribulin-d3 (mesylate) is a deuterium labeled Eribulin mesylate. Eribulin mesylate is a microtubule targeting agent that is used for the research of cancer.
Microtubule/Tubulin   Apoptosis  
Cancer  
/
HY-W012184 CDAP
CDAP is an organic cyanylating reagent that can be used for preparation of solid phase affinity reagents, modification of protein thiols and nucleotide delivery. CDAP also activates polysaccharides with a variety of chemical properties. CDAP can be used to prepare conjugate vaccines and other immune reagents.
Biochemical Assay Reagents  
Inflammation or Immune System Disease  
/
HY-P0325 V5 Epitope Tag Peptide TFA
V5 Epitope Tag Peptide TFA is a tag peptide derived from a small epitope present on the P and V proteins of the paramyxovirus of simian virus 5. V5 Epitope Tag Peptide TFA can be used for protein separation and purification, and competitive elution with target proteins.
Biochemical Assay Reagents  
/
HY-P3333 KSPWFTTL
KSPWFTTL is an immunodominant Kb-restricted epitope from the p15E transmembrane protein. KSPWFTTL can restore susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-171821 PF-08046054
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors
Antibody-Drug Conjugates (ADCs)   PD-1/PD-L1  
Cancer  
/
HY-P1587 IRBP (1-20), human
IRBP (1-20), human contains a major epitope for the H-2b haplotype. IRBP (1-20), human induces experimental autoimmune uveoretinitis (EAU) in H-2b mice.
MHC  
Inflammation or Immune System Disease  
/
HY-P4193 AH1
AH1 is an immunodominant MHC class I-restricted nonamer peptide recognized by CD8+ cytotoxic T lymphocytes. AH1 derives from the envelope protein (gp70) of an endogenous ecotropic murine leukemia virus and is presented by the MHC class I Ld molecule. AH1 can be used for the research of colorectal carcinoma.
MHC  
Cancer   Inflammation or Immune System Disease  
/
HY-116969 22(R)-Hydroxycholesterol
22 (R)-Hydroxycholesterol (Narthesterol) is a natural oxysterol, acting as a LXRα agonist that inhibits cancer cell proliferation. 22 (R)-Hydroxycholesterol activates LXRα-mediated upregulation of downstream ABCA1 expression, enhances apolipoprotein-dependent cholesterol efflux, reduces intracellular cholesterol content, and decreases the production of β-amyloid peptide. 22 (R)-Hydroxycholesterol induces the differentiation of human mesenchymal stem cells into functional dopaminergic neurons. 22 (R)-Hydroxycholesterol is applicable to research related to cancer, Alzheimer's disease, and Parkinson's disease.
Endogenous Metabolite   LXR   Amyloid-β   ATP-binding cassette (ABC) transporters  
Lipid Metabolism  
/
HY-P99189 Cixutumumab
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer.

Species: Human

IGF-1R  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Large Cell Lung Carcinoma   HER-2 Positive Breast Cancer   Metastatic Breast Cancer  
/
HY-P99339 Tebentafusp
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells.

Species: Human

Interleukin Related   TNF Receptor  
Cancer  
/
HY-131498 Mca-PLGL-Dpa-AR-NH2
MOCAc-PLGL (Dpa) AR (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) is a synthetic fluorescent substrate mainly used for in vitro enzymatic activity assays of MMP-7 (detection at 393 nm after excitation at 328 nm). MOCAc-PLGL (Dpa) AR is specifically cleaved and hydrolyzed by MMP-7 at the Gly-Leu peptide bond, allowing enzymatic activity to be monitored via fluorometry or HPLC (DMSO is usually added to ensure sufficient dissolution when determining kinetic parameters). MOCAc-PLGL (Dpa) AR is used to accurately evaluate the catalytic activity and pH dependence of recombinant mature human MMP-7 in vitro. MOCAc-PLGL (Dpa) AR is suitable for research on the mechanisms of tumor metastasis and invasion, particularly in fields such as prostate cancer, colon cancer, lung cancer and breast cancer.\n
Fluorescent Dye   MMP  
Cancer   Digestive System Cancer   Urogenital Cancer  
/
HY-P991028 Surovatamig
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma.

Species: Human

CD3   CD19   Interleukin Related   TNF Receptor   IFNAR  
Non-Hodgkin Lymphoma  
/
HY-P991015 Pasritamig
Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-P9954 Catumaxomab
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers.

Species: Human

CD3  
Cancer  
/
HY-P990688 Xaluritamig
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8+ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma.

Species: Human

CD3  
Castration-Resistant Prostate Cancer  
/
HY-P99392 Teclistamab
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).

Species: Human

CD3  
Cancer  
/
HY-P76124 VHL Protein, Human (His)
VHL protein is an important component of the von Hippel-Lindau ubiquitination complex and plays a key role in ubiquitination and proteasomal degradation. As a target recruitment subunit in the E3 ubiquitin ligase complex, VHL specifically recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions and regulates cellular responses to oxygen levels. VHL Protein, Human (His) is the recombinant human-derived VHL protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P71043 SNCG Protein, Human
SNCG proteins help maintain the integrity of neurofilament networks and may influence axonal structure during development and adulthood. In vitro, it enhances the sensitivity of neurofilament-H to calcium-dependent proteases. SNCG Protein, Human is the recombinant human-derived SNCG protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

/
HY-P70801 TNF RI/TNFRSF1A Protein, Human (His)
TNFRSF1A (TNF RI) protein has a high ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3 target gene that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate apoptosis, and function as a regulator of inflammation. TNF RI/TNFRSF1A Protein, Human (His) is expressed by E. coli with a 6*His tag at the N-terminus.

Species: Human; Source: E. coli

Cytokines and Growth Factors Receptor Proteins TNF Superfamily Cytokine Receptors TNF Receptor Superfamily

/
HY-P71703 p53 Protein, Rat (His)
The p53 protein acts as a tumor suppressor, regulates the cell cycle and induces growth arrest or apoptosis.It activates genes that inhibit cell division and trigger apoptosis by controlling the expression of various proteins.p53 Protein, Rat (His) is the recombinant rat-derived p53 protein, expressed by E.coli , with N-6*His labeled tag.

Species: Rat; Source: E. coli

/
HY-P71928 TFF1 Protein, Human
TFF1 protein functions as a mucous gel stabilizer, vital for fortifying the gastrointestinal mucosa against noxious agents. It contributes to the mucous layer's integrity, providing a crucial physical barrier for the gastrointestinal tract, safeguarding it from potential harm. TFF1's stabilizing role emphasizes its significance in preserving the mucosal barrier, essential for overall gastrointestinal health and protection. TFF1 Protein, Human is the recombinant human-derived TFF1 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Cytokines and Growth Factors

/
HY-P703091 BRCA1 Protein, Human
BRCA1 Protein, Human is the recombinant human-derived BRCA1, expressed by E. coli, with tag free labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P705518 Cellular tumor antigen P53/TP53 Protein, Human (His)
The cellular tumor antigen P53/TP53 is a tumor suppressor that can induce growth arrest or apoptosis in a variety of tumor types. It regulates the cell cycle by negatively controlling genes critical for division. Cellular tumor antigen P53/TP53, Human (His) is the recombinant human-derived Cellular tumor antigen P53/TP53 protein, expressed by E. coli, with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P7305 TNF RI/TNFRSF1A Protein, Human (CHO)
TNFRSF1A (TNF RI) protein has a high ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3 target gene that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate apoptosis, and function as a regulator of inflammation. TNFRSF1A Protein, Human (CHO) is expressed by CHO and has a transmembrane region (D41-N201) .

Species: Human; Source: CHO

Cytokines and Growth Factors Receptor Proteins TNF Superfamily Cytokine Receptors TNF Receptor Superfamily

/
HY-P72261 Wilms tumor protein/WT1 Protein, Human (His-SUMO)
Wilms tumor protein (WT1) is a key transcription factor that critically regulates cell development and survival by binding to 5'-GCG(T/G)GGGCG-3'. It oversees target genes such as erythropoietin (EPO) and is critical for the development of the genitourinary system. Wilms tumor protein/WT1 Protein, Human (His-SUMO) is the recombinant human-derived Wilms tumor protein/WT1 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P7677 BIN2 Protein, Human (His)
BIN2 Protein, Human (His) is a recombinant human bridging integrator 2 (BIN2) with a His tag.

Species: Human; Source: E. coli

/
HY-P72054 RCVRN Protein, Human (sf9, His-Myc)
The RCVRN protein is a calcium sensor that regulates phototransduction in cone and rod photoreceptors, enhancing the light sensitivity of cone photoreceptors in dark conditions. Under low light, it prolongs RHO/rhodopsin activation in rod photoreceptor cells by inhibiting GRK1-mediated phosphorylation. RCVRN Protein, Human (sf9, His-Myc) is the recombinant human-derived RCVRN protein, expressed by sf9 insect cells , with N-10*His, C-Myc labeled tag.

Species: Human; Source: Sf9 insect cells

/
HY-P71778 RCVRN Protein, Human (P.pastoris, His)
The RCVRN protein is a calcium sensor that regulates phototransduction in cone and rod photoreceptors, enhancing the light sensitivity of cone photoreceptors in dark conditions. Under low light, it prolongs RHO/rhodopsin activation in rod photoreceptor cells by inhibiting GRK1-mediated phosphorylation. RCVRN Protein, Human (P.pastoris, His) is the recombinant human-derived RCVRN protein, expressed by P. pastoris , with N-His labeled tag.

Species: Human; Source: P. pastoris

/
HY-P72443 TNF RI/TNFRSF1A Protein, Mouse
TNFRSF1A (TNF RI) protein has a high ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3 target gene that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate apoptosis, and function as a regulator of inflammation. TNF RI/TNFRSF1A Protein, Mouse is expressed by E. coli and has a transmembrane region (I22-A212).

Species: Mouse; Source: E. coli

Cytokines and Growth Factors CD Antigens Receptor Proteins TNF Superfamily Epithelial cell CD Proteins Endothelial cell CD Proteins Cytokine Receptors TNF Receptor Superfamily TNF-RI/CD120a

/
HY-P76849 CSAG1 Protein, Human (HEK293, Fc)
CSAG1 Protein is a potential key player in maintaining centrosome integrity during mitosis, impacting chromosome segregation. The mechanisms underlying its contribution to centrosome stability require elucidation. Its putative involvement highlights significance in mitosis-related cellular events. Further research is essential to unravel precise details of CSAG1's function and its implications for centrosome integrity during mitosis. CSAG1 Protein, Human (HEK293, Fc) is the recombinant human-derived CSAG1 protein, expressed by HEK293 , with N-hFc labeled tag.

Species: Human; Source: HEK293

/
HY-P73700 PRAC Protein, Human (His-SUMO)
PRAC Protein exhibits high expression in the prostate, rectum, and distal colon, with weaker expression in the bladder. Its prominence in prostate cancer cell lines suggests a potential link to prostate cancer pathology. The tissue-specific expression emphasizes PRAC Protein's potential roles in normal physiological processes and cancer contexts. PRAC Protein, Human (His-SUMO) is the recombinant human-derived PRAC protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

Species: Human; Source: E. coli

/
HY-P74657 p53 Protein, Rhesus Macaque
p53 protein, a tumor suppressor, induces growth arrest or apoptosis in various tumors, regulating cell division through gene control, including cyclin-dependent kinase inhibitors. It stimulates BAX and FAS antigen expression or represses Bcl-2 to induce apoptosis. p53's multifaceted role underscores its importance in orchestrating cellular responses, maintaining genomic integrity, and countering aberrant cell proliferation. p53 Protein, Rhesus Macaque is the recombinant Rhesus Macaque-derived p53 protein, expressed by E. coli , with tag free.

Species: Rhesus Macaque; Source: E. coli

/
HY-P703092 BRCA2 Protein, Human (HEK293, His, Strep, Flag)
BRCA2 Protein, Human (HEK293, His, Strep, Flag) is the recombinant human-derived BRCA2, expressed by HEK293, with Strep, His, Flag labeled tag.

Species: Human; Source: HEK293

/
HY-P706224 TNF-alpha/TNFSF2 Protein, Zebrafish (His)
TNF-α/TNFSF2 protein is a cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and has multiple biological functions. It has the ability to induce cell death in specific tumor cell lines, serves as a potent pyrogen, can cause fever through direct action or stimulation of interleukin-1 secretion, and is involved in the induction of cachexia. Animal-Free TNF-alpha/TNFSF2 Protein, Zebrafish (His) is the recombinant zebrafish-derived TNF-alpha/TNFSF2 protein, expressed by E. coli , with N-His labeled tag.

Species: Others; Source: E. coli

Cytokines and Growth Factors Neurotrophic Factors TNF-alpha

/
HY-P85931 Wilms Tumor Protein Antibody (YA5623)
Wilms Tumor Protein Antibody (YA5623) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Wilms Tumor Protein.

Host: Mouse; Reactivity: Human, Mouse, Rat, Pig

Monoclonal Antibodies Primary Antibodies

/
HY-P83702 Cytokeratin 17 Antibody (YA3438)
Cytokeratin 17 Antibody (YA3438) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytokeratin 17.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85903 Cytokeratin 17 Antibody (YA5595)
Cytokeratin 17 Antibody (YA5595) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cytokeratin 17.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P82532 Wilms Tumor Protein Antibody (YA2277)
Wilms Tumor Protein Antibody (YA2277) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86790 BRCA2 Antibody (YA6483)
BRCA2 Antibody (YA6483) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCA2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86827 CTAG1B Antibody (YA6520)
CTAG1B Antibody (YA6520) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CTAG1B.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P811127 Recoverin Antibody
Recoverin Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Recoverin.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P811296 CTAG1B Antibody
CTAG1B Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to CTAG1B.

Host: Rabbit; Reactivity: Human

Polyclonal Antibodies Primary Antibodies

/
HY-P82532A Wilms Tumor Protein Antibody (YA2277)(PBS only)
Wilms Tumor Protein Antibody (YA2277) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P83052 CEP55 Antibody (YA2797)
CEP55 Antibody (YA2797) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CEP55.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83052A CEP55 Antibody (YA2797)(PBS only)
CEP55 Antibody (YA2797) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CEP55.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86253 NABC1 Antibody (YA5945)
NABC1 Antibody (YA5945) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NABC1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86440 Wilms Tumor Protein Antibody (YA6132)
Wilms Tumor Protein Antibody (YA6132) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86753 MUC16 Antibody (YA6445)
MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86753A MUC16 Antibody (YA6445)(PBS only)
MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P86923 Wilms Tumor Protein Antibody(YA6616)
Wilms Tumor Protein Antibody(YA6616) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.

Host: Rabbit; Reactivity: Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P87366 BLCAP Antibody (YA7049)
BLCAP Antibody (YA7049) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to BLCAP.

Host: Mouse; Reactivity: Human, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P811181 TPD52L2 Antibody
TPD52L2 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to TPD52L2.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-K0603 Alcian Blue Staining Solution (pH 1.0)

MCE Alcian Blue Staining Solution (pH 1.0) is commonly used for selective detection of sulfated mucins in histological research, including cartilage staining, mucin type differentiation, and aiding in the identification of mucinous epithelial tumors.

Cell Biology Cell Analysis Staining Kit

/
HY-K0611 Modified Van Gieson Staining Kit

MCE Modified Van Gieson Staining Kit employs Celestine Blue and Mayer’s hematoxylin for nuclear staining, providing clearer and more stable nuclear visualization while facilitating longer preservation of stained sections. Ponceau S is used for collagen fiber staining, offering stable coloration and strong resistance to fading. This method enables effective differentiation between collagen fibers and muscle fibers, and can assist in distinguishing collagen fiber–derived tumors from myogenic tumors to a certain extent. It is also suitable for observing tissue or organ injury, repair processes, and the degree of fibrosis.

Cell Biology Cell Analysis Staining Kit

/
HY-K1067 Exosome Isolation and Purification Kit (From Tissue)

MCE Exosome Isolation and Purification Kit (From Tissue) provides a simple and effective method to isolate and purify intact exosomes from a variety of tissues (such as brain, heart, lung, liver, muscle, lymph nodes, thymus, embryo, tumor, etc.).

Cell Biology Cell Analysis Exosome Isolation, Purification and Detection

/
HY-K6006 Basement Membrane Matrix IPSC-qualified

MCE Basement Membrane Matrix IPSC-qualified is primarily composed of natural basement membrane matrix extracted from mouse tumors. This product is mainly used for stem cells culture.

Cell Biology 3D Cell Culture Basement Membrane Matrix

/
HY-K6012 Tissue Dissociation Solution

MCE Tissue Dissociation Solution is able to gently and efficiently dissociate tissue samples into cell suspensions or cell aggregates, which can then be used for the subsequent construction of tumor organoids.

Cell Biology 3D Cell Culture Organoid Research

/
HY-K6101 Human Breast Cancer Organoid Kit

MCE Human Breast Cancer Organoid Kit contains Breast Cancer Organoid Basal Medium A, Breast Cancer Organoid Supplement B (50×), Breast Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human breast cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6103 Human Small Cell Lung Cancer Organoid Kit

MCE Human Small Cell Lung Cancer Organoid Kit contains Small Cell Lung Cancer Organoid Basal Medium A, Small Cell Lung Cancer Organoid Supplement B (50×),Small Cell Lung Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human small cell lung cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6104 Human Colorectal Cancer Organoid Kit

MCE Human Colorectal Cancer Organoid Kit contains Colorectal Cancer Organoid Basal Medium A, Colorectal Cancer Organoid Supplement B (50×), Colorectal Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human colorectal cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6107 Human Cervical Cancer Organoid Kit

MCE Human Cervical cancer Organoid Kit contains Cervical cancer Organoid Basal Medium A, Cervical cancer Organoid Supplement B (50×), Cervical cancer Organoid Supplement C (250×). This product can be used to efficiently construct human cervical cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6108 Human Esophageal Cancer Organoid Kit

MCE Human Esophageal Cancer Organoid Kit contains Esophageal Cancer Organoid Basal Medium A, Esophageal Cancer Organoid Supplement B (50×), Esophageal Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human esophageal cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6109 Human Endometrial Cancer Organoid Kit

MCE Human Endometrial Cancer Organoid Kit contains Endometrial Cancer Organoid Basal Medium A, Endometrial Cancer Organoid Supplement B (50×), Endometrial Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human endometrial cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6110 Human Pancreatic Cancer Organoid Kit

MCE Human Pancreatic Cancer Organoid Kit contains Pancreatic Cancer Organoid Basal Medium A, Pancreatic Cancer Organoid Supplement B (50×), Pancreatic Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human pancreatic cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6123 Human Ovarian Cancer Organoid Kit

MCE Human Ovarian Cancer Organoid Kit includes a basic culture medium for ovarian cancer organoids, as well as culture supplements, and is designed for the effective construction of human ovarian cancer organoids.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6126 Human Kidney Cancer Organoid Kit

MCE Human Kidney Cancer Organoid Kit includes a basic culture medium for Kidney Cancer organoids, as well as culture supplements, and is designed for the effective construction of human Kidney Cancer organoids.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/

Keywords

artificial intelligence | tumor epitope prediction | neoantigens | HLA binding | immunopeptidomics | personalized cancer vaccines